Lifestyle modifications (including diet and exercise) and pharmacological agents (such as peroxisome proliferator-activated receptor (PPAR)-α agonists, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)) all target inflammation in various ways, and thus can reduce MS-associated complications. The gene discussed is PPARA; the disease is myeloid sarcoma.